Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q1 2023 · 10-Q
Revenue$11.91M$11.91M+44.7% vs Q1 2022 Net Income-$12.03M-$12.03MN/M vs Q1 2022 EPS Diluted-$0.63-$0.63N/M vs Q1 2022 Gross Profit$7,898,000+58.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Operating Cash Flow-$11,574,000N/M Free Cash Flowderived-$11,689,000N/M Margins · derivedGross margin66.3%+5.6 pt vs Q1 2022
Operating margin-94.5%+25.1 pt vs Q1 2022
Net margin-101.0%+31.0 pt vs Q1 2022
ended Mar 31, 2023 · filed May 11, 2023 · 41 d after period end